27.02
+2.31%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beam Therapeutics
From its filings with the US Securities and Exchange Commission
Beam Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BEAM. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $139.7m and a net loss of $80.0m. At that date it held total assets of $1.48bn and shareholders' equity of $1.24bn.
We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.
Our suite of gene editing technologies is anchored by our proprietary base editing technology, which potentially enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the DNA. This approach uses a chemical reaction designed to create precise, predictable and efficient genetic outcomes at the targeted sequence. Our proprietary base editors have two principal components: (i) a clustered regularly interspaced short palindromic repeats, or CRISPR, protein, bound to a guide RNA, that leverages the established DNA-targeting ability of CRISPR, but is modified to not cause a double-stranded break, and (ii) a base editing enzyme, such as a deaminase, which carries out the desired chemical modification of the target DNA base. We believe this design contributes to a more precise and efficient edit compared to traditional gene editing methods, with the potential to dramatically increase the impact of gene editing. We are also pursuing a suite of delivery modalities, including both ex vivo and in vivo approaches, depending on tissue type.
Quoted from its 10-K, filed 24 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Feb 2020
- Employees
- 511
- Website
- beamtx.com ↗
- Head office
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Giuseppe CiaramellaPresident$3.4m
- Mr. John EvansChief Executive Officer, Principal Accounting Officer, Director, since 2017$6.4m
- Mr. Sravan EmanyChief Financial and Principal Financial Officer$4.8m
- Dr. Amy SimonChief Medical Officer$2.6m
- Dr. Christine BellonChief Legal Officer and Secretary$2.6m
- Dr. Mark FishmanLead Independent Director$485,201
- Mr. Graham CooperIndependent Director$450,241
- Mr. Chirfi GuindoIndependent Director$774,595
- Dr. Carole HoIndependent Director$449,100
- Dr. John MaraganoreIndependent Director$447,035
- Ms. Christi ShawIndependent Director$444,394
- Ms. Kathleen WalshIndependent Director$447,741
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 77
- Social
- 80
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beam Therapeutics Inc is equipped with advanced gene editing technologies such as base editing and prime editing, which enable precise modifications to genetic material. This positions the company at the forefront of the gene therapy industry, offering potential treatments for a wide range of genetic diseases.
- Beam Therapeutics holds a robust intellectual property portfolio, including numerous patents related to its gene editing technologies. This creates a barrier to entry for competitors and provides the company with long-term exclusivity, enhancing its competitive advantage in the market.
- The company is comprised of a talented team of scientists, researchers, and industry experts who possess extensive knowledge and expertise in gene editing and therapeutic development. Their collective skills contribute to the successful execution of Beam Therapeutics' projects and drive innovation within the organization.
- Beam Therapeutics has established strategic collaborations and partnerships with leading academic institutions and pharmaceutical companies. These alliances provide access to additional resources, technologies, and expertise, enabling the company to accelerate research and development efforts and expand its product pipeline.
Weaknesses
- At present, Beam Therapeutics has a relatively limited product portfolio, with only a few candidates in various stages of development. This restricts the company's revenue potential and increases its dependency on the success of a limited number of therapeutic programs.
- As with any gene editing technology, Beam Therapeutics faces regulatory and ethical challenges associated with the use of such technologies in human therapies. The company needs to navigate complex regulatory frameworks and address public concerns surrounding gene manipulation, which could potentially delay product approvals or limit market acceptance.
- The gene therapy market is highly competitive, with numerous companies actively pursuing gene editing technologies and therapeutic solutions. Beam Therapeutics faces the challenge of differentiating itself from competitors, both in terms of technological advancements and market positioning, to capture and maintain significant market share.
Opportunities
- The demand for gene therapies is expected to increase as the understanding of genetic diseases expands and the need for targeted treatment options becomes more apparent. Beam Therapeutics has the opportunity to leverage its expertise and technology to develop novel therapies to address unmet medical needs.
- The versatility of Beam Therapeutics' gene editing technologies allows the company to explore and expand its presence in various therapeutic areas beyond its current focus. By diversifying its product pipeline, the company can tap into new markets and address a wider range of genetic diseases.
Threats
- Gene editing technologies, although promising, may carry inherent risks and safety concerns. Any adverse events or unexpected outcomes related to the use of Beam Therapeutics' therapies could lead to setbacks in clinical trials, regulatory challenges, or loss of public trust, impacting the company's overall success.
- The biotechnology sector, including gene therapy companies like Beam Therapeutics, often face market volatility influenced by factors such as regulatory changes, healthcare policies, economic conditions, and investor sentiment. Fluctuations in the market can impact the company's financial stability, ability to raise funds, and investor confidence.
- Reimbursement for gene therapies is still evolving, and uncertain reimbursement models can pose challenges for the adoption and commercialization of innovative treatments. Beam Therapeutics needs to carefully navigate the reimbursement landscape to ensure adequate pricing and reimbursement coverage for its therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.